electroCore Inc. (ECOR)
15.88
-0.02 (-0.13%)
At close: Jan 21, 2025, 3:59 PM
15.70
-1.13%
After-hours Jan 21, 2025, 07:32 PM EST
Company Description
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies.
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years.
The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
electroCore Inc.
| Country | United States |
| IPO Date | Jun 22, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Daniel S. Goldberger |
Contact Details
Address: 200 Forge Way Rockaway, New Jersey United States | |
| Website | https://www.electrocore.com |
Stock Details
| Ticker Symbol | ECOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001560258 |
| CUSIP Number | 28531P103 |
| ISIN Number | US28531P2020 |
| Employer ID | 20-3454976 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Daniel S. Goldberger | Chief Executive Officer & Director |
| Joshua S. Lev | Chief Financial Officer |
| Carrie Kochek | Senior Director of Human Resources |
| Donald Melnikoff | Senior Vice President of Engineering, Regulatory & Compliance |
| Dr. Peter S. Staats M.B.A., M.D. | Chief Medical Officer |
| Dr. Thomas J. Errico M.D. | Founder & Independent Director |
| Manuel A. Marques | Senior Vice President of Operations |
| Michael Mansfield | Vice President of Marketing |
| Michael Romaniw | Executive Vice President of Systems & Operations |
| Mitch Deshon | Vice President of Global Sales & Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 17, 2025 | 4 | Filing |
| Jan 17, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Nov 29, 2024 | 424B5 | Filing |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 15, 2024 | D | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 04, 2024 | 3 | Filing |
| Sep 06, 2024 | 8-K | Current Report |